https://www.attovia.com/publications/efficacy-and-safety-of-a-single-dose-of-atto-1310-a-novel-anti-il-31-attobody-fc-fusion-protein-interim-results-from-a-randomized-double-blind-placebo-controlled-phase-1b-study-in-patients-with-at/ 2026-09-23T18:38:23+00:00 https://www.attovia.com/publications/ultra-sensitive-detection-of-circulating-il-31-reveals-elevated-levels-across-pruritic-skin-diseases/ 2026-09-23T18:38:38+00:00 https://www.attovia.com/publications/safety-pharmacokinetics-and-pharmacodynamics-of-atto-1310-a-novel-anti-il-31-attobody-fc-fusion-protein-in-healthy-adults/ 2026-09-23T18:39:12+00:00 https://www.attovia.com/publications/preclinical-characterization-of-atto-2306-a-long-acting-bispecific-antibody-targeting-il-13-and-il-31-for-type-2-inflammatory-skin-diseases/ 2026-09-25T20:13:40+00:00